Open-label adjunctive topiramate in the treatment of bipolar disorders

Biological Psychiatry

Volumn 47, Issue 12, 2000, Pages 1025-1033

  McElroy, Susan L ^a   Suppes, Trisha ^b   Keck Jr , Paul E ^a   Frye, Mark A ^c,d   Denicoff, Kirk D ^e   Altshuler, Lori L ^c,d   Brown, E Sherwood ^b   Nolen, Willem A ^f   Kupka, Ralph W ^f   Rochussen, Jennifer ^g   Leverich, Gabriele S ^e   Post, Robert M ^h  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^e NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g Stanley Foundation Data Coordinating Center   (United States)

^h NONE

Author keywords

Bipolar disorders; Cycling; Mania; Topiramate; Weight

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LITHIUM; TOPIRAMATE; VALPROIC ACID;

ADD ON THERAPY; ADULT; ANOREXIA; ARTICLE; BODY MASS; BODY WEIGHT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIC DEPRESSIVE PSYCHOSIS; NEUROTOXICITY; OUTPATIENT; PRIORITY JOURNAL; RATING SCALE; SYMPTOM; WEIGHT REDUCTION;

ADULT; ANTICONVULSANTS; BIPOLAR DISORDER; BODY MASS INDEX; FEMALE; FRUCTOSE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS;

EID: 0034128399     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00316-9     Document Type: Article

References (36)

1. American Psychiatric Association (1994): Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association.
2. Ben-Menachem E (1995): Topiramate. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic Drugs, 4th ed. New York: Raven, 1063-1070.
3. Ben-Menachem E., Henriksen O., Dam M., Mikkelsen M., Schmidt D., Reid S., et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial epilepsy. Epilepsia. 37:1996;539-543.
4. Calabrese JR, Bowden CB, Woyshville MJ (1995): Lithium and anticonvulsants in the treatment of bipolar disorder. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: The Fourth Generation of Progress. New York: Raven1099-1111.
5. Calabrese J.R., Bowden C.L., Sachs G.S., Ascher J.A., Monaghan E., Rudd G.D. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry. 60:1999;79-88.
6. Calabrese JR, Keck PE Jr, McElroy SL, Werkner JE (1998, June): Topiramate in severe treatment-refractory mania. Abstract presented at the annual meeting of the American Psychiatric Association, Toronto.
7. Chengappa K.N.R., Rathmore D., Levine J., Atzert R., Solai L., Parepally H., et al. Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disord. 1:1999;42-53.
8. Dixon J.F., Hokin L.E. The antibipolar drug valproate mimics lithium in stimulating glutamate release and inositol 1,4,5-triphosphate accumulation in brain cortex slices but not accumulation of inositol monophosphates and biphosphates. Proc Natl Acad Sci U S A. 94:1997;4757-4760.
9. Dixon J.F., Hokin L.E. Lithium acutely inhibits and chronically upregulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortices. Proc Natl Acad Sci U S A. 95:1998;8363-8368.
10. Faught E., Wilder B.J., Ramsay R.E., Reife R.A., Kramer L.D., Pledger G.W., et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology. 46:1996;1684-1690.
11. First M.P., Spitzer R.L., Gibbon M., Williams J.B.W. Structural Clinical Interview for DSM-IV Axis I Disorders, Research Version, 2/96 Final. 1996;New York State Psychiatric Institute, Biometrics Research Department, New York.
12. Gordon A., Price L.H. Mood stabilization and weight loss with topiramate. Am J Psychiatry. 156:1999;968-969.
13. Hough C.J., Irwin R.P., Gao X.-M., Rogawski M.A., Chuang D.-M. Carbamazepine inhibition of N-methyl-D-aspartate-evoked calcium influx in rat cerebellar granule cells. J Pharmacol Exp Ther. 276:1996;143-149.
14. Johannessen S.I. Pharmacokinetics and interaction profile of topiramate Review and comparison with other newer antiepileptic drugs . Epilepsia. 38:(suppl 1):1996;S18-S23.
15. Keck P.E. Jr, McElroy S.L. Drugs for treatment of bipolar disorder Antiepileptic drugs . Schatzberg A.S., Nemeroff C.B. The American Psychiatric Press Textbook of Psychopharmacology. 1998;431-454 American Psychiatric Press, Washington, DC. 2nd ed.
16. Kusumaker V, Lakshmi N, Yatham MB, O'Donovan CA, Kutcher SP (1999, May): Topiramate in rapid cycling bipolar women. Abstract presented at the annual meeting of the American Psychiatric Association, Washington, DC.
17. Langtry H.D., Gillis J.C., Davis R. Topiramate A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy . Drugs. 54:1997;752-773.
18. Leverich GS, Nolen W, Rush AJ, McElroy SL, McElroy SL, Keck PE Jr, et al (in press): The longitudinal methods of the Stanley Foundation Bipolar Outcome Network. J Affect Disord.
19. Leverich G.S., Post R.M. Life charting of affective disorders. CNS Spectrums. 3:1998;21-37.
20. Marcotte D. Use of topiramate, a new antiepileptic as a mood stabilizer. J Affect Disord. 50:1998;245-251.
21. Meldrum B.S. Update on the mechanism of action of antiepileptic drugs. Epilepsia. 37:(suppl):1996;4-11.
22. Muller D., Joly M., Lynch G. Contributions of quisqualate and NMDA receptors to the induction and expression of LTP. Science. 242:1988;1694-1697.
23. Nonaka S., Hough C.J., Chuang D.M. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci U S A. 95:1998;2642-2647.
24. Norton J., Potter D., Edwards K. Sustained weight loss associated with topiramate. Epilepsia. 38:(suppl 3):1997;58.
25. Petty F., Rush A.J., David J.M., Calabrese J.M., Kimmel S.E., Kramer G.L., et al. Plasma GABA predicts acute response to divalproex in mania. Biol Psychiatry. 39:1996;278-284.
26. Post R.M., Denicoff K.D., Frye M.A. A history of the use of anticonvulsants as mood stabilizers in the last two decades of the 20th century. Neuropsychobiology. 38:1998;152-166.
27. Privitera M., Fincham R., Penry J., Reife R., Kramer L., Pledger G., et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Neurology. 46:1996;1678-1683.
28. Rosenfeld W.E., Schaefer P.A., Pace K. Weight loss patterns with topiramate therapy. Epilepsia. 38:(suppl 3):1997;60.
29. Rush A.J., Giles D.E., Schlesser M.A., Fulton C.L., Weissenburger J., Burns C. The Inventory for Depressive Symptomatology (IDS) Preliminary findings . Psychiatry Res. 18:1985;65-87.
30. Sachdeo R.C., Reife R.A., Lim P., Pledger G. Topiramate monotherapy for partial onset seizures. Epilepsia. 38:1997;294-300.
31. Sharief M., Viteri C., Ben-Menachem E., Weber M., Reife R., Pledger G., et al. Double-blind, placebo-controlled study of topiramate in patients with refractory epilepsy. Epilepsy Res. 25:1996;217-224.
32. Spearing M.K., Post R.M., Leverich G.S., Brandt D., Nolen W. Modification of the Clinical Global Impression (CGI) scale for use in bipolar illness (BP) The CGI-BP . Psychiatry Res. 73:1997;159-171.
33. Suppes T, Leverich GS, Keck PE Jr, Nolen W, Denicoff KD, Altshuler LL, et al (in press): The Stanley Foundation Bipolar Network: Demographics and illness characteristics of the first 261 patients with bipolar disorder. J Affect Disord.
34. Tassinari C.A., Michelucci R., Chauvel P., Chodkiewicz J., Shorvon S., Henriksen O., et al. Double-blind, placebo-controlled trial of topiramate (600mg daily)as add-on therapy for the treatment of refractory partial epilepsy. Epilepsia. 37:1996;763-768.
35. Tocco G., Maren S., Shors T.J., Baudry M., Thompson R.F. Long-term potentiation is associated with increased [3H] AMPA binding in rat hippocampus. Brain Res. 573:1992;228-234.
36. Young R.C., Biggs J.T., Ziegler V.E., Meyer D.A. A rating scale for mania Reliability, validity and sensitivity . Br J Psychiatry. 133:1978;429-435.